Immunogenetics: Open Access
Open Access

Rheumatoid Arthritis and Bone Health: Strategies to Prevent Osteoporosis and Joint Damage

Jianxiong Min^{* *}Correspondence: Jianxiong Min, Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou, China, Email:

Author info »

Description

Rheumatoid Arthritis (RA) is a long-lasting autoimmune disorder that primarily impacts the joints, leading to inflammation, discomfort and swelling [1]. While the joint-related symptoms are the most noticeable, RA also significantly impacts bone health, leading to conditions like osteoporosis. Osteoporosis, characterized by a reduction in bone density and increased fracture risk, is a common concern for RA patients. This dual challenge of inflammation-induced joint damage and bone thinning complicates the management of RA, making it essential to address both issues simultaneously [2]. Preventing osteoporosis and preserving joint health are key goals in the comprehensive care of individuals with RA.

Osteoporosis in rheumatoid arthritis

Osteoporosis is a significant complication for people with RA, as inflammation from the disease accelerates bone resorption, while bone formation is impaired [3]. Chronic inflammation causes an imbalance in the bone remodeling process by stimulating the activity of osteoclasts (cells responsible for breaking down bone) and inhibiting osteoblasts (cells that form bone). As a result, RA patients often experience bone density loss, making them more prone to fractures [4].

The use of corticosteroids, a common treatment for managing inflammation in RA, exacerbates the risk of osteoporosis. Long-term corticosteroid therapy reduces calcium absorption, hinders bone formation and weakens bones. Reduced mobility in RA patients due to joint pain also contributes to bone demineralization and muscle weakness, further increasing the risk of osteoporosis [5].

Strategies to prevent osteoporosis and joint damage

Disease-modifying medications: Disease Modifying Antirheumatic Drugs (DMARDs), especially biologic therapies, are essential in managing RA [6]. By targeting the underlying inflammatory processes, these treatments help prevent further joint damage and reduce inflammation. Controlling the disease’s inflammatory activity also helps protect bone health by minimizing the conditions that lead to bone loss. Medications such as methotrexate, TNF inhibitors and JAK inhibitors help maintain disease remission, thereby reducing the likelihood of osteoporosis [7].

Minimizing corticosteroid : While corticosteroids are effective in controlling inflammation, they should be used at the lowest effective dose for the shortest duration possible [8]. Prolonged use of corticosteroids accelerates bone loss and increases fracture risk. For patients requiring long-term corticosteroid therapy, bone-protecting medications should be considered in conjunction with steroids.

Bone-strengthening medications: Medications like bisphosphonates or denosumab are used to prevent bone resorption and improve bone density in RA patients. These treatments can help reduce the risk of fractures. In more severe cases, teriparatide, a synthetic form of parathyroid hormone, can stimulate new bone formation. These medications are often recommended for patients who have significant bone loss or are on long-term corticosteroid therapy.

Calcium and vitamin D: Adequate intake of calcium and vitamin D is essential for maintaining healthy bones. Patients with RA are at risk of deficiencies in these nutrients, either due to dietary limitations or side effects from medications. Calcium helps build and maintain bone strength, while vitamin D is important for calcium absorption. Ensuring sufficient intake through supplements or diet can help mitigate the risk of osteoporosis. Typically, 1,000 mg of calcium and 800-1,000 IU of vitamin D per day is recommended for RA patients.

Lifestyle modifications: Smoking and excessive alcohol consumption are both risk factors for osteoporosis and can worsen RA symptoms. Smoking impairs blood flow to the bones, reducing bone density, while excessive alcohol interferes with calcium absorption and disrupts bone metabolism [9]. Quitting smoking and limiting alcohol consumption can significantly improve bone health and overall disease management for RA patients.

Regular bone density monitoring: RA patients, especially those on long-term corticosteroids or those with risk factors for osteoporosis, should undergo routine monitoring of bone density [10]. A Dual Energy X-ray Absorptiometry (DEXA) scan can help detect early bone loss, allowing for timely interventions. Early detection allows for preventative treatments to reduce the risk of fractures and improve bone health over time.

Conclusion

Rheumatoid arthritis poses a significant risk to both joint and bone health. Osteoporosis is a common complication in RA patients, driven by chronic inflammation and the use of corticosteroid medications. However, with appropriate and comprehensive management, the risk of osteoporosis and joint damage can be significantly reduced. Early and effective disease control through DMARDs and biologic therapies is important for minimizing inflammation and preventing further damage to both the joints and bones. By focusing on both the prevention of osteoporosis and the management of RA, healthcare providers can help improve the quality of life for individuals with rheumatoid arthritis. With a personalized, proactive approach, it is possible to reduce the risk of fractures, preserve joint function and ultimately enhance the long-term health of RA patients.

References

1. Ismail M, Hasan H, El-Orfali Y, Ismail H, Khawaja G. Anti‐inflammatory, antioxidative and hepatoprotective effects of trans Δ9‐tetrahydrocannabinol/sesame oil on adjuvant‐induced arthritis in rats. Evid Based Complement Alternat Med. 2018;2018(1):9365464.

   [Crossref] [Google Scholar] [PubMed]

2. Desai N, Tambe V, Pofali P, Vora LK. Cell membrane‐coated nanoparticles: A new frontier in immunomodulation. Adv Nanobiomed Res. 2024;2024(23):2400012.

   [Crossref] [Google Scholar]

3. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-2102.

   [Crossref] [Google Scholar] [PubMed]

4. Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone turnover markers: basic biology to clinical applications. Endocr Rev. 2023;44(3):417-473.

   [Crossref] [Google Scholar] [PubMed]  

5. Athanazio RA, Silva LV, Vergara AA, Ribeiro AF, Riedi CA, Procianoy ED, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumo. 2017;43:219-245.

   [Crossref] [Google Scholar] [PubMed]

6. Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J. 2021;42(42):4389-4400.

   [Crossref] [Google Scholar] [PubMed]

7. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126.

   [Crossref] [Google Scholar] [PubMed]

8. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, et al. European consensus guidelines on the management of respiratory distress syndrome-2019 update. Neonatology. 2019;115(4):432-450.

   [Crossref] [Google Scholar] [PubMed]  

9. Virk MS, Virk MA, He Y, Tufail T, Gul M, Qayum A, et al. The anti-nflammatory and curative exponent of probiotics: A comprehensive and authentic ingredient for the sustained functioning of major human organs. Nutrients. 2024;16(4):546.

   [Crossref] [Google Scholar] [PubMed] 

10. Nabarrete JM, Pereira AZ, Garófolo A, Seber A, Venancio AM, Grecco CE, et al. Brazilian nutritional consensus in hematopoietic stem cell transplantation: children and adolescents. Einstein (Sao Paulo). 2021;19:eAE5254.

    [Crossref] [Google Scholar] [PubMed]